- Home
- FLC vs FENC Comparison
FLC vs FENC Comparison
Compare FLC & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$10.30
Company Overview
Basic Information| Metric | FLC | FENC |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.9M | 384.0M |
| IPO Year | 2003 | 2010 |
Fundamental Metrics
Financial Performance| Metric | FLC | FENC |
|---|---|---|
| Price | $15.64 | $10.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 35.8K | ★ 160.4K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $62.55 |
| Revenue Next Year | N/A | $42.10 |
| P/E Ratio | ★ N/A | $178.33 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.54 | $5.65 |
| 52 Week High | $18.09 | $13.25 |
Technical Indicators
Market Signals| Indicator | FLC | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 27.43 | 43.64 |
| Support Level | N/A | $10.09 |
| Resistance Level | $17.00 | $11.29 |
| Average True Range (ATR) | 0.12 | 0.43 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 17.65 | 46.77 |
Price Performance
Historical Comparison FLC
FENC
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.